| Name | Title | Contact Details |
|---|
We are passionate about improving people`s daily lives by offering clinically proven solutions to common skin and eye care problems through digital channels, traditional domestic retailers, and international distributors. We are in the process of growing from a small single-product company into a profitable mid-sized multi-product company. Our leading product, Avenova®, is the only lid & lash solution that brings eyes back to life by setting the highest standards of purity and efficacy. We pioneered the use of hypochlorous acid in the eyecare space and intend on making Avenova a household name. Our motto is, “If you have eyes, you need Avenova!” We also recently acquired DERMAdoctor, LLC, a skincare company offering more than 30 dermatologist-developed skincare products. We plan to launch nine new products this year with the founder of DERMAdoctor doing well known media placements such as QVC.
"Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers` delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment. "
DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
With modern, attractive clinical offices in Annapolis, Glen Burnie, Hagerstown, Prince Frederick, Leonardtown, Kent Island, and Easton, 19 board certified physicians, 7 physician assistants, 2 certified nurse practitioners, a full service cosmetic lase...